VIS and Vaccine Code Set Updates, September 22, 2023
Release Notes: This release covers code updates for Vaccine Information Statement (VIS) codes and maps. It also includes selected vaccine code set file updates.
These release notes address code updates for the following:
- VIS Code Set Updates: A new CDC document type has been added to the VIS code sets. A Recipient-Caregiver Immunization Information Statement (IIS) has been created similar to a VIS which is to be provided when the nirsevimab monoclonal antibody is administered.
- The new document title is “RSV (Respiratory Syncytial Virus) preventative antibody IIS” and it will have an edition date of September 25, 2023.
- VIS codes have been updated to include this document in order to facilitate automation and workflow for end users who may wish to integrate these codes into their systems.
- New RSV CVX Codes: Two new unspecified RSV codes have been added:
- CVX code 314 is an RSV vaccine unspecified code
- CVX code 315 is an RSV monoclonal antibody unspecified code
- CPT Code Corrections: AMA has corrected the CPT code descriptions for codes 91318 and 91319 to reflect the correct dose volume of 0.3 mL
The following files have been updated on the CDC website to reflect the changes in this release:
- VIS Barcode Lookup Table
- CVX to VIS
- VIS URLs
- CVX Report
- CVX to Vaccine Group
- CPT to CVX
Code Set Update Details
- VIS Code Set Updates:
VIS codes are created to enable provider systems to implement VIS scanning and to help automate capture of the specific VIS document edition given to the recipient or caregiver. VIS codes may be published in advance of the actual VIS document publication, but they are only in effect and useable starting on the edition date of the VIS. The URLs included in the code set will not point to the new edition until the VIS document edition date or shortly thereafter.
This release includes the following VIS related code additions:
New IIS first edition added: “RSV (Respiratory Syncytial Virus) preventative antibody IIS”, dated 09/25/2023. This first edition IIS is for the new RSV nirsevimab pediatric monoclonal antibody, not for the RSV vaccine. In the code set files, the following has been added for the new VIS edition record:
- VIS Document Type Description: “RSV (Respiratory Syncytial Virus) preventative antibody IIS” (*)
- New document identifier, “VIS Fully-encoded text string”: 253088698300062211230925
- “Edition Date”: 09/25/2023
- “Date of Last Update”: 09/25/2023
- “Edition Status”: Current
- “GDTI”: 0886983000622
- New URLs:
Note: (*) VIS Document Type Descriptions in the VIS vaccine code set may not be exactly the same as the final published VIS document title.
- Two CVX codes have been associated to this VIS code:
- 306, “Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 0.5 mL, neonates and children to 24 months”
- 307, “Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 1 mL, neonates and children to 24 months”
- New RSV CVX Codes: Two new unspecified CVX codes for RSV have been added and associated to Vaccine Group “RSV”.
CVX Code | CVX Description | CVX Short Description | CVX Note | CVX Status |
|---|
314 | Respiratory syncytial virus (RSV) vaccine, unspecified | Respiratory syncytial virus (RSV) vaccine, unspecified | Unspecified, for historic records where the specific vaccine administered is not known | Inactive |
|---|
315 | Respiratory syncytial virus (RSV) monoclonal antibody (MAB), unspecified | Respiratory syncytial virus (RSV) MAB, unspecified | Unspecified, for historic records where the specific RSV MAB administered is not known | Inactive |
|---|
In addition, a note has been added to RSV unspecified CVX code 304, “Respiratory syncytial virus (RSV), unspecified” to differentiate its use from the new unspecified CVX codes listed above. The CVX Note field now reads as “Unspecified, for historic records where it is not known if RSV vaccine or RSV MAB was administered”.
- CPT Code Corrections: AMA has corrected the CPT code descriptions for codes 91318 and 91319 to reflect the correct dose volume of 0.3 mL, previously listed as 0.2 mL.
CPT Code | CPT Description | CPT Short Description |
|---|
91318 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | SARSCOV2 VAC 3MCG TRS-SUC IM |
|---|
91319 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | SARSCV2 VAC 10MCG TRS-SUC IM |
|---|
